NUVISAN’s Discovery Pharmacology experts also support projects to identify and/or deconvolute disease-relevant targets across a variety of therapeutic areas. Using our state-of-the-art functional genomics and cellular assay platforms we offer both in vitro and in vivo
- the development of disease-relevant cellular 2D and 3D models
- CRISPR- and RNAi-based target screening and validation
- the establishment of customized readouts
- transcriptomic and proteomic profiling
Our in vitro, ex vivo, and in vivo models are complemented by the analysis of human samples. This assay portfolio enables us to perform thorough mode-of-action studies to optimize your compounds. We also utilize these assays to facilitate identification and validation of pharmacodynamic and predictive biomarkers. With our advanced in silico analysis tools, together with a diverse panel of disease-relevant in vitro and in vivo models, our cross-indication research team supports the indication expansion and repurposing of your existing assets.
Thus, we assist you to
- get an innovative and substantiated start for your drug development program
- enable early de-risking of your drug discovery project through target validation
- find and optimize a lead by delivering high-quality data to explore structure–activity relationships
- evaluate and preclinically validate target engagement/pharmacodynamic and predictive biomarkers
- identify the most suitable proof-of-concept indication for your asset
The following links provide further information:
With decades of industry experience, our interdisciplinary teams have the knowledge, skills, and equipment to drive your project to the next level. Get in Touch now!